CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 24, 2003
Result type: Reports
Project Number: SR0005-000
Product Line: Reimbursement Review

Generic Name: Almotriptan

Brand Name: Axert

Manufacturer: Janssen-Ortho Inc.

Therapeutic Area: Migraine

Indications: Migraine

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 27, 2004

Recommendation Type: List in a similar manner to other drugs in class